Multi-cancer early detection tests are being sold on emotion, not evidence. Hannah and Lena cut through the hype to discuss what the data actually shows — and what real tools for risk assessment and data-driven cancer screening look like, and why they matter far more than the marketing suggests.

One of the most prominent voices in breast cancer research joins the show to discuss how we screen, how we treat, and the diagnostic and systemic gaps that are costing women their lives — and the system billions.

Yes, drugs are expensive. But the bigger, less-discussed problem is that most drugs don’t work for most patients — and we’re paying for them anyway. Hannah and Lena make the case for why diagnostics that identify who will and won’t respond are the missing piece of the drug pricing conversation.

Hannah and Lena introduce the show and explain why they’re doing it: to pull back the curtain on the financial misalignments built into the healthcare system that prevent patients from getting better care. If you’ve ever wondered why the system feels rigged — this is where we start.